TWI748062B - Ｈｅｒ２陽性乳癌之輔助治療 - Google Patents

Ｈｅｒ２陽性乳癌之輔助治療 Download PDF

Info

Publication number
TWI748062B
TWI748062B TW107106709A TW107106709A TWI748062B TW I748062 B TWI748062 B TW I748062B TW 107106709 A TW107106709 A TW 107106709A TW 107106709 A TW107106709 A TW 107106709A TW I748062 B TWI748062 B TW I748062B
Authority
TW
Taiwan
Prior art keywords
pertuzumab
her2
trastuzumab
patients
cancer
Prior art date
Application number
TW107106709A
Other languages
English (en)
Chinese (zh)
Other versions
TW201832781A (zh
Inventor
馬克 C 班尤內斯
格拉罕 亞歷山大 羅斯
Original Assignee
美商建南德克公司
瑞士商赫孚孟拉羅股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61691568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI748062(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 美商建南德克公司, 瑞士商赫孚孟拉羅股份公司 filed Critical 美商建南德克公司
Publication of TW201832781A publication Critical patent/TW201832781A/zh
Application granted granted Critical
Publication of TWI748062B publication Critical patent/TWI748062B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
TW107106709A 2017-03-02 2018-03-01 Ｈｅｒ２陽性乳癌之輔助治療 TWI748062B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762466239P 2017-03-02 2017-03-02
US62/466,239 2017-03-02
US201762469317P 2017-03-09 2017-03-09
US62/469,317 2017-03-09
US201762486876P 2017-04-18 2017-04-18
US62/486,876 2017-04-18

Publications (2)

Publication Number Publication Date
TW201832781A TW201832781A (zh) 2018-09-16
TWI748062B true TWI748062B (zh) 2021-12-01

Family

ID=61691568

Family Applications (3)

Application Number Title Priority Date Filing Date
TW107106709A TWI748062B (zh) 2017-03-02 2018-03-01 Ｈｅｒ２陽性乳癌之輔助治療
TW110145536A TWI792743B (zh) 2017-03-02 2018-03-01 Her2陽性乳癌之輔助治療
TW112106134A TWI831617B (zh) 2017-03-02 2018-03-01 Her2陽性乳癌之輔助治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW110145536A TWI792743B (zh) 2017-03-02 2018-03-01 Her2陽性乳癌之輔助治療
TW112106134A TWI831617B (zh) 2017-03-02 2018-03-01 Her2陽性乳癌之輔助治療

Country Status (22)

Country Link
US (5) US11077189B2 (cg-RX-API-DMAC10.html)
EP (2) EP3589661B1 (cg-RX-API-DMAC10.html)
JP (4) JP6992081B2 (cg-RX-API-DMAC10.html)
KR (4) KR102417583B1 (cg-RX-API-DMAC10.html)
CN (5) CN114984206A (cg-RX-API-DMAC10.html)
AU (3) AU2018227788B2 (cg-RX-API-DMAC10.html)
CA (1) CA3048918C (cg-RX-API-DMAC10.html)
DK (1) DK3589661T5 (cg-RX-API-DMAC10.html)
ES (1) ES2969041T3 (cg-RX-API-DMAC10.html)
FI (1) FI3589661T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20240069T1 (cg-RX-API-DMAC10.html)
HU (1) HUE064898T2 (cg-RX-API-DMAC10.html)
IL (3) IL301279B2 (cg-RX-API-DMAC10.html)
LT (1) LT3589661T (cg-RX-API-DMAC10.html)
MX (2) MX388169B (cg-RX-API-DMAC10.html)
PL (1) PL3589661T3 (cg-RX-API-DMAC10.html)
PT (1) PT3589661T (cg-RX-API-DMAC10.html)
RS (1) RS65204B1 (cg-RX-API-DMAC10.html)
SI (1) SI3589661T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202400129T1 (cg-RX-API-DMAC10.html)
TW (3) TWI748062B (cg-RX-API-DMAC10.html)
WO (1) WO2018160654A2 (cg-RX-API-DMAC10.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2110138A1 (en) * 1999-08-27 2009-10-21 Genentech, Inc. Dosages for treatment of anti-erbB2 antibodies
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
HUE044352T2 (hu) 2011-10-14 2019-10-28 Hoffmann La Roche Pertuzumab, Trastuzumab, Docetaxel és Carboplatin korai stádiumú mellrák kezelésére
MY173295A (en) 2013-04-16 2020-01-14 Genentech Inc Pertuzumab variants and evaluation thereof
US10380152B2 (en) * 2016-01-19 2019-08-13 International Business Machines Corporation Cognitive system comparison and recommendation engine
DK3570884T3 (da) 2017-01-17 2020-11-30 Genentech Inc Subkutane HER2-antistofformuleringer
HUE064898T2 (hu) 2017-03-02 2024-04-28 Genentech Inc HER2-pozitív emlõrák adjuváns kezelése
MX2020009824A (es) 2018-07-25 2021-01-15 Alteogen Inc Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma.
CN112203642B (zh) * 2019-03-25 2025-03-07 阿特根公司 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物
WO2020205807A1 (en) * 2019-03-29 2020-10-08 The Board Of Trustees Of The Leland Stanford Junior University Methods of treatments based upon anthracycline responsiveness
US20220204644A1 (en) * 2019-05-02 2022-06-30 Mab Discovery Gmbh Combination of her2 antibodies
TW202615652A (zh) 2020-01-23 2026-04-16 南韓商阿特根公司 新穎的具有改善的穩定性的玻尿酸酶變異體及含有其的醫藥組合物
KR20230027068A (ko) * 2020-05-29 2023-02-27 시아겐 인크. 트라스투주맙 및 옥살리플라틴-기반 화학요법과 병용하여 투카티닙을 이용하는 her2 양성 암의 치료 방법
JP2023532122A (ja) * 2020-06-29 2023-07-26 ジェネンテック， インコーポレイテッド ペルツズマブにトラスツズマブを加えた固定用量配合剤
WO2022031093A1 (ko) 2020-08-07 2022-02-10 (주)알테오젠 재조합 히알루로니다제의 생산 방법
IL311003A (en) 2021-08-25 2024-04-01 Denali Therapeutics Inc Anti-2HER antibodies and methods of using them
CN113943805A (zh) * 2021-11-02 2022-01-18 上海市生物医药技术研究院 基因突变检测引物组及其用途
CN117224689B (zh) * 2023-11-16 2024-02-23 上海复宏汉霖生物技术股份有限公司 联合抗her2抗体和化疗剂治疗胃癌的用途

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1985003357A1 (en) 1984-01-30 1985-08-01 Icrf Patents Ltd. Improvements relating to growth factors
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
CA1339946C (en) 1987-03-31 1998-07-07 Michael J. Griffith Ultrapurification process for polypeptides
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
EP0474727B1 (en) 1989-05-19 1997-07-23 Genentech, Inc. Her2 extracellular domain
EP0494135B1 (en) 1989-09-29 1996-04-10 Oncogene Science, Inc. Human "neu" related protein p100 and use of the same for detecting preneoplastic or neoplastic cells in a human
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
ES2293661T3 (es) 1996-11-27 2008-03-16 Genentech, Inc. Purificacion por afinidad de polipeptido en una matriz de proteinas a.
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
PT1064027E (pt) 1998-03-27 2008-09-29 Genentech Inc Sinergismo de ligando de apo-2 e anticorpo anti-her-2
ATE370961T1 (de) 1998-05-06 2007-09-15 Genentech Inc Reinigung von antikörpern durch ionenaustauschchromatographie
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
SI1187632T1 (sl) 1999-05-14 2009-04-30 Genentech Inc Zdravljenje z anti-ErbB2 protitelesi
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US20040013667A1 (en) 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US20030086924A1 (en) 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
AR024464A1 (es) 1999-06-25 2002-10-02 Genentech Inc Anticuerpos anti-erbb2 humanizados.
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
DE60033658T2 (de) 1999-06-25 2007-11-22 Genentech, Inc., South San Francisco Behandlung von prostata-krebs mit anti-erbb2 antikörpern
EP2110138A1 (en) 1999-08-27 2009-10-21 Genentech, Inc. Dosages for treatment of anti-erbB2 antibodies
US20200048362A1 (en) 2000-03-16 2020-02-13 Immunogen, Inc. Methods of treatment using anti-erbb antibody-maytansinoid conjugates
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
WO2001089566A1 (en) 2000-05-19 2001-11-29 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
US20030232399A1 (en) 2000-06-14 2003-12-18 Robertson John Forsyth Russell Cancer detection methods and reagents
US6984494B2 (en) 2000-08-15 2006-01-10 Genentech, Inc. Analytical method
EP1345968A2 (en) 2000-12-28 2003-09-24 Altus Biologics Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
US6695940B2 (en) 2001-04-05 2004-02-24 Alan D. Devoe Laminate thin-wall ceramic tubes, including with integral stress wrappings, thickened ends and/or internal baffles, particularly for solid oxide fuel cells
US20030040509A1 (en) 2001-08-06 2003-02-27 Genomed, Llc Methods and compositions for treating diseases associated with excesses in ACE
EP1300146A1 (en) 2001-10-03 2003-04-09 Boehringer Ingelheim International GmbH Pharmaceutical composition for the treatment of animal mammary tumors
US20040048525A1 (en) 2002-01-28 2004-03-11 Sagucio Esteban N. Watercycle for wet rider
JP2005522514A (ja) 2002-04-10 2005-07-28 ジェネンテック・インコーポレーテッド 抗ｈｅｒ２抗体改変体
NZ535992A (en) 2002-05-17 2008-11-28 Aventis Pharma Sa Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
HUP0600340A3 (en) 2002-07-15 2011-06-28 Genentech Inc Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
US6982719B2 (en) 2002-07-15 2006-01-03 Sun Microsystems, Inc. Switching sample buffer context in response to sample requests for real-time sample filtering and video generation
US7129840B2 (en) 2002-09-03 2006-10-31 Ricoh Company, Ltd. Document security system
PT1543038T (pt) 2002-09-11 2017-07-07 Genentech Inc Purificação de proteína
US20060100168A1 (en) 2002-09-30 2006-05-11 The Trustee Of Boston University Method of treating cancer using adenosine and its analogs
EP1572972A4 (en) 2002-11-21 2007-11-21 Genentech Inc THERAPY OF NON-MALIGNER DISEASES OR DISORDER WITH ANTI-ERBB2 ANTIBODIES
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
WO2004098508A2 (en) 2003-04-30 2004-11-18 Napro Biotherapeutics, Inc. Methods for production of non-disease causing hemoglobin by ex vivo oligonucleotide gene editing of human stem/progenitor cells
JP4599355B2 (ja) 2003-07-28 2010-12-15 ジェネンテック， インコーポレイテッド プロテインａアフィニティークロマトグラフィーの間のプロテインａの浸出の低減
AU2005232657B2 (en) 2004-04-08 2010-12-16 David B. Agus ErbB antagonists for pain therapy
AU2005249360B2 (en) 2004-04-12 2011-07-21 Medimmune, Llc Anti-IL-9 antibody formulations and uses thereof
US7195440B2 (en) 2004-05-27 2007-03-27 Lambert Charles F Agricultural silo auger system apparatus and method
NZ551180A (en) 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
SV2006002143A (es) 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
UA90480C2 (uk) 2004-07-22 2010-05-11 Джэнэнтэк, Инк. Фармацевтична композиція, що має протипухлинну активність, яка включає антитіло до her2
CA2577133A1 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2005300315A1 (en) 2004-11-04 2006-05-11 Pfizer Products Inc. CTLA-4 antibody and aromatase inhibitor or combination treatment for breast cancer
CA2587519A1 (en) 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a her inhibitor
EP3698807A1 (en) 2005-01-21 2020-08-26 Genentech, Inc. Fixed dosing of her antibodies
CN103169729A (zh) 2005-02-18 2013-06-26 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
RS53128B (sr) 2005-02-23 2014-06-30 Genentech Inc. Produžavanje vremena progresije bolesti ili preživljavanja kod pacijenata obolelih od kancera jajnika korišćenjem pertuzumaba
US20060204505A1 (en) 2005-03-08 2006-09-14 Sliwkowski Mark X Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
US20060212956A1 (en) 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US20070009976A1 (en) 2005-07-06 2007-01-11 Helmut Lenz Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
US20090148401A1 (en) 2005-12-05 2009-06-11 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of binding partners
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
AU2007254950A1 (en) 2006-05-31 2007-12-13 Thallion Pharmaceuticals Incorporated Methods, compositions, and kits for treating Shiga toxin associated conditions
AU2007259171A1 (en) 2006-06-05 2007-12-21 F. Hoffmann-La Roche, Ag Extending survival of cancer patients with elevated levels of EGF or TGF-alpha
AU2007287794B2 (en) 2006-08-21 2013-03-28 F. Hoffmann-La Roche Ag Tumor therapy with an anti-VEGF antibody
WO2008031531A1 (en) 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
MX2009008981A (es) 2007-03-02 2009-09-02 Genentech Inc Prediccion de respuesta a un inhibidor her.
EP1997534A1 (en) 2007-05-31 2008-12-03 Pierre Fabre Medicament Cancer treatment combination therapy comprising vinflunine and trastuzumab
AU2008258859A1 (en) 2007-06-06 2008-12-11 F.Hoffmann-La Roche Ag Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a NIR fluorescence label
WO2008154249A2 (en) 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
BRPI0816769A2 (pt) 2007-09-12 2016-11-29 Hoffmann La Roche combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso
WO2009051815A1 (en) 2007-10-19 2009-04-23 Bipar Sciences, Inc. Methods and compositions for the treatment of cancer using benzopyrone-type parp inhibitors
HUE024877T2 (en) 2007-10-30 2016-02-29 Genentech Inc Antibody purification by cation exchange chromatography
WO2009064738A2 (en) 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
US20090203015A1 (en) 2008-02-13 2009-08-13 Celera Corporation Multiplex assays for hormonal and growth factor receptors, and uses thereof
CL2009000545A1 (es) 2008-03-06 2010-10-15 Genentech Inc Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer.
NZ587706A (en) 2008-03-18 2012-12-21 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
US9235334B2 (en) 2008-05-09 2016-01-12 Genesis Industries, Llc Managing landbases and machine operations performed thereon
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
WO2010042705A1 (en) 2008-10-09 2010-04-15 Medimmune, Llc Antibody formulation
KR20180117734A (ko) 2008-11-22 2018-10-29 제넨테크, 인크. 유방암의 치료를 위한, 화학요법과 조합된 항-ｖｅｇｆ 항체의 용도
CN102413839A (zh) 2009-03-06 2012-04-11 医学免疫有限责任公司 人源化抗cd19抗体制剂
US20120121586A1 (en) 2009-05-29 2012-05-17 Astrid Kiermaier Modulators for her2 signaling in her2 expressing patients with gastric cancer
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
TWI423980B (zh) 2009-09-28 2014-01-21 Hoffmann La Roche 苯并氧氮呯ｐｉ３ｋ抑制劑化合物及使用方法
WO2011069074A2 (en) 2009-12-04 2011-06-09 Genentech, Inc. Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2012078771A1 (en) 2010-12-09 2012-06-14 Genentech, Inc. Treatment of her2-positive cancer with paclitaxel and trastuzumab-mcc-dm1
WO2012120004A1 (en) 2011-03-07 2012-09-13 F. Hoffmann-La Roche Ag In vivo selection of therapeutically active antibodies
HUE044352T2 (hu) * 2011-10-14 2019-10-28 Hoffmann La Roche Pertuzumab, Trastuzumab, Docetaxel és Carboplatin korai stádiumú mellrák kezelésére
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
WO2013096812A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Articles of manufacture and methods for co-administration of antibodies
CN104379163A (zh) 2012-06-08 2015-02-25 霍夫曼-拉罗奇有限公司 用于治疗癌症的磷酸肌醇3激酶抑制剂化合物和化疗剂的突变选择性及组合
DK2884979T3 (da) 2012-08-17 2019-09-02 Hoffmann La Roche Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib
RU2692773C2 (ru) 2012-11-30 2019-06-27 Ф.Хоффманн-Ля Рош Аг Идентификация пациентов, нуждающихся в совместной терапии с использованием ингибитора pd-l1
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
MY173295A (en) 2013-04-16 2020-01-14 Genentech Inc Pertuzumab variants and evaluation thereof
ES2763429T5 (es) 2013-12-17 2023-06-21 Hoffmann La Roche Procedimientos de tratamiento de cánceres usando antagonistas de la unión al eje de PD-1 y taxanos
BR112016024789A2 (pt) 2014-04-25 2017-10-24 Genentech Inc métodos de tratamento de câncer de mama em fase inicial com trastuzumabe-mcc-dm1 e pertuzumabe
HUE044139T2 (hu) 2015-07-07 2019-09-30 Hoffmann La Roche Kombinált terápia egy HER2-ellenes antitest-gyógyszer konjugátummal és bcl-2 inhibitorral
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
FR3056576B1 (fr) 2016-09-29 2020-02-07 Easyl Procede de fabrication de diglyceroxyde de calcium
EP3534948A1 (en) * 2016-11-04 2019-09-11 Genentech, Inc. Treatment of her2-positive breast cancer
JP6914336B2 (ja) 2016-12-28 2021-08-04 ジェネンテック， インコーポレイテッド 進行したｈｅｒ２発現がんの治療
DK3570884T3 (da) 2017-01-17 2020-11-30 Genentech Inc Subkutane HER2-antistofformuleringer
HUE064898T2 (hu) * 2017-03-02 2024-04-28 Genentech Inc HER2-pozitív emlõrák adjuváns kezelése
HRP20260181T1 (hr) 2017-10-20 2026-03-27 BioNTech SE Priprema i skladištenje lipozomskih rnk formulacija koje su pogodne za terapiju
JP2023532122A (ja) 2020-06-29 2023-07-26 ジェネンテック， インコーポレイテッド ペルツズマブにトラスツズマブを加えた固定用量配合剤
AU2021308283A1 (en) 2020-07-14 2023-02-02 F. Hoffmann-La Roche Ag Assays for fixed dose combinations
MX2023006793A (es) 2020-12-11 2023-06-20 Genentech Inc Tratamientos conjuntos para tratamiento de cancer her2.
TW202400230A (zh) 2022-03-14 2024-01-01 美商建南德克公司 乳癌的組合療法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Phase III APHINITY Study Shows Genentech’s Perjeta® Regimen Helped People with an Aggressive Type of Early Breast Cancer Live Longer without their Disease Returning Compared to Herceptin® and Chemotherapy.",Wednesday, Mar 1, 2017,網址:https://www.gene.com/media/press-releases/14655/2017-03-01/phase-iii-aphinity-study-shows-genentech.
Hoffmann-La Roche,"A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer.",November 2, 2016,網址:https://clinicaltrials.gov/ct2/history/NCT01358877?V_112=View#StudyPageTop.
Hoffmann-La Roche,"A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer.",November 2, 2016,網址:https://clinicaltrials.gov/ct2/history/NCT01358877?V_112=View#StudyPageTop.;" *
Jasmeet C Singh, et al."Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience."Oncologist. 2017 Feb;22(2):139-143. *
Phase III APHINITY Study Shows Genentech’s Perjeta® Regimen Helped People with an Aggressive Type of Early Breast Cancer Live Longer without their Disease Returning Compared to Herceptin® and Chemotherapy.",Wednesday, Mar 1, 2017,網址:https://www.gene.com/media/press-releases/14655/2017-03-01/phase-iii-aphinity-study-shows-genentech.; *

Also Published As

Publication number Publication date
IL289297B1 (en) 2023-05-01
TW202211932A (zh) 2022-04-01
JP7270701B2 (ja) 2023-05-10
US20240252634A1 (en) 2024-08-01
CN114984206A (zh) 2022-09-02
SI3589661T1 (sl) 2024-03-29
LT3589661T (lt) 2024-02-12
TWI831617B (zh) 2024-02-01
HRP20240069T1 (hr) 2024-03-29
US11077189B2 (en) 2021-08-03
EP3589661A2 (en) 2020-01-08
ES2969041T3 (es) 2024-05-16
PL3589661T3 (pl) 2024-04-08
US11992529B2 (en) 2024-05-28
KR20220100996A (ko) 2022-07-18
MX2021014137A (es) 2022-01-04
DK3589661T3 (da) 2024-01-22
WO2018160654A3 (en) 2018-12-20
IL301279B2 (en) 2024-06-01
JP2022028681A (ja) 2022-02-16
KR20210111882A (ko) 2021-09-13
JP6992081B2 (ja) 2022-02-03
HUE064898T2 (hu) 2024-04-28
CA3048918A1 (en) 2018-09-07
TWI792743B (zh) 2023-02-11
AU2021205081B2 (en) 2023-08-24
EP4368199A3 (en) 2024-08-21
TW201832781A (zh) 2018-09-16
AU2021205081A1 (en) 2021-08-12
US20210330789A1 (en) 2021-10-28
MX388169B (es) 2025-03-19
AU2018227788B2 (en) 2021-04-22
US20250018032A1 (en) 2025-01-16
PT3589661T (pt) 2024-01-29
US20180250397A1 (en) 2018-09-06
RS65204B1 (sr) 2024-03-29
CA3048918C (en) 2023-04-25
CN116531511A (zh) 2023-08-04
CN110337450A (zh) 2019-10-15
US12128103B2 (en) 2024-10-29
CN116850283A (zh) 2023-10-10
IL301279B1 (en) 2024-02-01
CN117180422A (zh) 2023-12-08
US11638756B2 (en) 2023-05-02
MX2019010296A (es) 2019-11-21
IL289297B2 (en) 2023-09-01
WO2018160654A2 (en) 2018-09-07
JP2024001062A (ja) 2024-01-09
AU2023237217B2 (en) 2024-05-30
IL289297A (en) 2022-02-01
KR20190096384A (ko) 2019-08-19
IL268394B (en) 2022-03-01
JP2023071672A (ja) 2023-05-23
FI3589661T3 (fi) 2024-01-31
IL301279A (en) 2023-05-01
JP2020509024A (ja) 2020-03-26
AU2018227788A1 (en) 2019-07-18
EP4368199A2 (en) 2024-05-15
IL268394A (en) 2019-09-26
KR20230144110A (ko) 2023-10-13
TW202335682A (zh) 2023-09-16
AU2023237217A1 (en) 2023-10-26
EP3589661B1 (en) 2023-11-01
DK3589661T5 (da) 2024-09-02
SMT202400129T1 (it) 2024-05-14
US20230000977A1 (en) 2023-01-05
CN110337450B (zh) 2023-07-25
IL268394B2 (en) 2023-09-01
KR102417583B1 (ko) 2022-07-07

Similar Documents

Publication Publication Date Title
AU2021205081B2 (en) Adjuvant treatment of HER2-positive breast cancer
HK40109409A (en) Adjuvant treatment of her2-positive breast cancer
HK40070880A (en) Adjuvant treatment of her2-positive breast cancer
HK40097418A (en) Adjuvant treatment of her2-positive breast cancer
HK40015029A (en) Adjuvant treatment of her2-positive breast cancer
HK40015029B (en) Adjuvant treatment of her2-positive breast cancer